Categories: News

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, Jan. 22, 2021 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

Boston Scientific Corporation (BSX)
Class Period: 4/24/2019 – 11/16/2020
Lead Plaintiff Motion Deadline: February 2, 2021
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nyse-bsx/  

Splunk Inc. (SPLK)
Class Period: 10/21/2020 – 12/2/2020
Lead Plaintiff Motion Deadline: February 2, 2021
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-splk/  

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner, Lewis Kahn, toll-free at 1-877-515-1850, via email (Lewis.Kahn@KSFcounsel.com), or via the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

Staff

Recent Posts

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

1 hour ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

2 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

16 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

19 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

19 hours ago